THE EFFECTIVE USE OF BEZAFIBRATE AS A SECOND LINE THERAPY FOR PRIMARY BILIARY CHOLANGITIS

被引：0
|
作者：
Howden, Adam [1 ]
Valliani, Talal [1 ]
机构：
[1] North Bristol NHS Trust Liver Unit, Bristol, Avon, England
来源：
GUT | 2021年 / 70卷
关键词：
D O I：
10.1136/gutjnl-2021-BASL.32
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P023
引用
收藏
页码：A21 / A22
页数：2
相关论文
共 50 条
  • [31] New Guidelines on primary biliary Cholangitis: Obeticholic Acid (Ocaliva®) considered as the only approved Second-line Therapy
    不详
    VISCERAL MEDICINE, 2017, 33 (05) : 392 - 392
  • [32] EFFECTIVE LONGTERM THERAPY OF PRIMARY HYPERLIPOPROTEINEMIAS WITH BEZAFIBRATE
    SCHIFFL, H
    WEIDMANN, P
    FRAGIACOMO, C
    NOSEDA, G
    BACHMANN, C
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 115 (26) : 907 - 911
  • [33] Baseline Characteristics and Risk Profiles of 1111 Patients with Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
    Hirschfield, Gideon
    Kowdley, Kris
    Kremer, Andreas
    Vierling, John
    Bowlus, Christopher
    Levy, Cynthia
    Mayo, Marlyn
    Crittenden, Daria
    Standen, Mary
    Yang, Ke
    Choi, Yun-Jung
    McWherter, Charles
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1171 - S1171
  • [34] Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?
    Bittermann, Therese
    Schaubel, Douglas E.
    HEPATOLOGY, 2024,
  • [35] Baseline characteristics and risk profiles of 1111 patients with primary biliary cholangitis (PBC) in need of second-line therapy
    Hirschfield, Gideon
    Kowdley, Kris
    Kremer, Andreas E.
    Vierling, John M.
    Bowlus, Christopher
    Levy, Cynthia
    Mayo, Marlyn J.
    Crittenden, Daria B.
    Standen, Mary
    Yang, Ke
    Choi, Yun-Jung
    McWherter, Charles
    JOURNAL OF HEPATOLOGY, 2023, 78 : S371 - S372
  • [36] IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate
    Takano, Keiko
    Saeki, Chisato
    Oikawa, Tsunekazu
    Hidaka, Akihisa
    Mizuno, Yusuke
    Ishida, Jinya
    Takakura, Kazuki
    Nakano, Masanori
    Torisu, Yuichi
    Amano, Katsushi
    Ishikawa, Tomohisa
    Zeniya, Mikio
    Tsubota, Akihito
    Saruta, Masayuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (04) : 663 - 672
  • [37] Bezafibrate for the treatment of primary sclerosing cholangitis
    Mizuno, Suguru
    Hirano, Kenji
    Tada, Minoru
    Yamamoto, Keisuke
    Yashima, Yoko
    Yagioka, Hiroshi
    Kawakubo, Kazumichi
    Ito, Yukiko
    Kogure, Hirofumi
    Sasaki, Takashi
    Arizumi, Toshihiko
    Togawa, Osamu
    Matsubara, Saburo
    Nakai, Yousuke
    Sasahira, Naoki
    Tsujino, Takeshi
    Isayama, Hiroyuki
    Kawabe, Takao
    Omata, Masao
    Koike, Kazuhiko
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (07) : 758 - 762
  • [38] Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
    Reig, Anna
    Sese, Pilar
    Pares, Albert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (01): : 49 - 55
  • [39] In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response
    Korula, Jacob
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (08) : JC45 - JC45
  • [40] BEZAFIBRATE ALLEVIATES PRURITUS AND DECREASES SPECIFIC CIRCULATING METABOLITES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
    Reig, A.
    Perez-Cormenzana, M.
    Sese, P.
    Mayo, R.
    Castro, A.
    Pares, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S429 - S429
12345